Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.69 |
| ▸ | MAG | P20916 | 6/20 | 0.63 |
| ▸ | SELL | P14151 | 1/20 | 0.63 |
| ▸ | SELP | P16109 | 1/20 | 0.63 |
| ▸ | CD22 | P20273 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL804936 | 1.00 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL29412465 | 1.00 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL30001019 | 1.00 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL14362275 | 1.00 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL19922284 | 1.00 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL24628357 | 1.00 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL12454161 | 1.00 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL30185416 | 0.98 | SIGLEC7 (0.66) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL31700860 | 0.97 | SIGLEC7 (0.68) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL30970760 | 0.97 | SIGLEC7 (0.70) | SIGLEC7MAGSELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3893675-B1 | STABLE AQUEOUS COMPOSITION COMPRISING OLIGOSACCHARIDES | NESTLE SA (CH) | 2026-04-15 | — | — | EP | claimed |
| EP-4072319-B1 | COMPOSITIONS FOR USE IN THE REDUCTION OF NOCICEPTION AND OTHER HEALTH BENEFITS IN INFANTS AND YOUNG CHILDREN | NESTLE SA (CH) | 2026-04-01 | — | — | EP | claimed |
| US-20260083785-A1 | USES OF BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISM | NESTLE SA (CH) | 2026-03-26 | — | — | US | claimed |
| EP-3727038-B1 | COMPOSITIONS FOR USE IN THE REDUCTION OF NOCICEPTION IN INFANTS AND YOUNG CHILDREN | NESTLE SA (CH) | 2026-02-25 | — | — | EP | claimed |
| WO-2025242902-A1 | OLIGOSACCHARIDE MIXTURE FOR BRAIN DEVELOPMENT | N.V. NUTRICIA (NL) | 2025-11-27 | — | — | WO | claimed |
| EP-4593853-A1 | USES OF BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISM | Société des Produits Nestlé S.A. (CH) | 2025-08-06 | — | — | EP | claimed |
| US-20250221440-A1 | A METHOD FOR PROVIDING AN AMORPHOUS HMO PRODUCT BY DRYING | DSM IP ASSETS BV (NL) | 2025-07-10 | — | — | US | claimed |
| EP-4581126-A1 | PROCESS FOR THE PRODUCTION OF A PURIFIED HUMAN MILK OLIGOSACCHARIDE DERIVED FROM A MICROBIAL FERMENTATION PROCESS | Chr. Hansen A/S (DK) | 2025-07-09 | — | — | EP | claimed |
| EP-4572618-A1 | KIT TO PROMOTE DEVELOPMENTAL MYELINATION | Société des Produits Nestlé S.A. (CH) | 2025-06-25 | — | — | EP | claimed |
| WO-2025099322-A1 | COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES | DSM IP ASSETS B.V. (NL) | 2025-05-15 | — | — | WO | claimed |
| WO-2022200337-A1 | HUMAN MILK OLIGOSACCHARIDES | Société des Produits Nestlé S.A. (CH) | 2022-09-29 | — | — | WO | claimed |
| WO-2022157280-A1 | NEW MAJOR FACILITATOR SUPERFAMILY (MFS) PROTEIN (FRED) IN PRODUCTION OF SIALYLATED HMOS | GLYCOM A/S (DK) | 2022-07-28 | — | — | WO | claimed |
| US-20220233561-A1 | HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT OF SYMPTOMS IN A PATIENT SUFFERING FROM NON-COELIAC WHEAT AND / OR GLUTEN SENSITIVITY | GLYCOM A/S (DK) | 2022-07-28 | — | — | US | claimed |
| WO-2022129518-A1 | SYNTHETIC NUTRITIONAL COMPOSITIONS TAILORED FOR CHINESE INFANTS | Société des Produits Nestlé S.A. (CH) | 2022-06-23 | — | — | WO | claimed |
| WO-2022129556-A1 | COMPOSITIONS FOR USE IN PROMOTING ACCELERATED BUTYRATE PRODUCTION IN YOUNG CHILDREN | Société des Produits Nestlé S.A. (CH) | 2022-06-23 | — | — | WO | claimed |
| WO-2022130322-A1 | SEPARATION OF CHARGED OLIGOSACCHARIDES | GLYCOM A/S (DK) | 2022-06-23 | — | — | WO | claimed |
| EP-3452051-B1 | COMPOSITION COMPRISING HMOS FOR USE IN THE TREATMENT OF MAST CELL MEDIATED VISCERAL HYPERSENSITIVITY AND/OR PAIN | GLYCOM AS (DK) | 2022-06-01 | — | — | EP | claimed |
| EP-3983076-A1 | HUMAN MILK OLIGOSACCHARIDES AND COMPOSITIONS THEREOF FOR USE IN PREVENTING, MANAGING OR TREATING SYMPTOMS RELATED TO MIGRAINE | Glycom A/S (DK) | 2022-04-20 | — | — | EP | claimed |
| EP-3980025-A1 | HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT OF SYMPTOMS IN A PATIENT SUFFERING FROM NON-COELIAC WHEAT AND/OR GLUTEN SENSITIVITY | Glycom A/S (DK) | 2022-04-13 | — | — | EP | claimed |
| US-20220089629-A1 | AMORPHOUS SIALYLATED OLIGOSACCHARIDES | GLYCOM A/S (DK) | 2022-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089629-A1 | AMORPHOUS SIALYLATED OLIGOSACCHARIDES | FUT6, ST3GAL3, NEU3 | SIGLEC7 9/4885MAG 583/4885SELL 1160/4885 |
| US-20260083785-A1 | USES OF BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISM | ST3GAL3, FUT5, FUT6 | SIGLEC7 50/4885MAG 2085/4885SELL 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.